Literature DB >> 12763502

Gastrointestinal disorders of the critically ill. Shock liver.

Christian P Strassburg1.   

Abstract

Shock liver describes a collecting pool of critically ill patients in whom the elevation of liver function tests or overt hepatic dysfunction is apparent. Different grades of shock liver affect about 50% of all intensive-care patients, varying from a mild elevation of serum aminotransferase and bilirubin levels in septic patients to an acute onset of high serum aminotransferases after haemodynamic shock. Abnormalities can subside within days or progressively deteriorate when persistent hepatic microcirculatory failure is present. Although hepatic injury in critically ill patients influences mortality rates it is underdiagnosed. The underlying pathophysiology involves changes in the portal and arterial blood supply as well as in microcirculation. Cross-talk between hepatocytes, Kupffer cells and endothelial cells, leading to an inflammatory response mediated primarily by tumour necrosis factor-alpha (TNF-alpha), is central to shock liver. The liver is a victim of shock inducers, and can also be the orchestrator of the inflammatory response syndrome (IRS). Hepatic injury by TNF-alpha is modulated by the prevalent pro-inflammatory or anti-inflammatory mediator profile elaborated by Kupffer cells. Kupffer cells additionally participate in the clearance of endotoxin, bacteria and inflammatory mediators and are thereby capable of preventing IRS. The hepatocyte undergoes dramatic alterations in synthetic activity, biliary transport, bile flow and glucose metabolism. Although standard determinations of aminotransferases, coagulation studies, glucose, lactate and bilirubin can detect hepatic injury they only partially reflect the cellular mechanisms driving shock liver. The management of shock liver is focused on the prevention of precipitating causes by controlling sepsis, circulation parameters and metabolism in addition to the cautious monitoring of therapeutic measures that can increase hepatic injury, which include intravenous nutrition, mechanical ventilation and catecholamine administration.

Entities:  

Mesh:

Year:  2003        PMID: 12763502     DOI: 10.1016/s1521-6918(03)00025-8

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  16 in total

Review 1.  Approach to clinical syndrome of jaundice and encephalopathy in tropics.

Authors:  Anil C Anand; Hitendra K Garg
Journal:  J Clin Exp Hepatol       Date:  2014-06-06

Review 2.  [Hepatic dysfunction in patients with cardiogenic shock].

Authors:  Philipp Kasper; Frank Tacke; Hans-Michael Steffen; Guido Michels
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-09-19       Impact factor: 0.840

3.  Effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on endothelial dysfunction, lipid peroxidation, and hepatocyte morphology in rats with sepsis-induced liver damage.

Authors:  Eray Kara; Ahmet Var; Seda Vatansever; Serap Cilaker; Yavuz Kaya; Teoman Coşkun
Journal:  Curr Ther Res Clin Exp       Date:  2004-05

4.  Clinical features of ischemic hepatitis caused by shock with four different types: a retrospective study of 328 cases.

Authors:  Gang Guo; Xian-Zheng Wu; Li-Jie Su; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Jaundice in critical illness: promoting factors of a concealed reality.

Authors:  Nicola Brienza; Lidia Dalfino; Gilda Cinnella; Caterina Diele; Francesco Bruno; Tommaso Fiore
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

6.  Liver aminotransferases are elevated with rhabdomyolysis in the absence of significant liver injury.

Authors:  Kathryn Weibrecht; Matthew Dayno; Chad Darling; Steven B Bird
Journal:  J Med Toxicol       Date:  2010-09

7.  Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion.

Authors:  Wu Deng; Laurie Farricielli
Journal:  BMJ Case Rep       Date:  2013-09-16

8.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

Review 9.  Cirrhosis and hepatopulmonary syndrome.

Authors:  Gokhan Tumgor
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

10.  Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome.

Authors:  Gokhan Tumgor; Afig Berdeli; Cigdem Arikan; Ertürk Levent; Sema Aydogdu
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.